On 30 July, Ambev S.A. (NYSE:ABEV) announced its results for the 2015 second quarter. During the second quarter, we paid approximately R$ 1.6 billion in interest on capital to shareholders and repurchased circa R$ 400 million of Ambev shares, which brought the YTD total payout figure close to R$ 7 billion or a 17% increase versus the same period of last year (including dividends, IOC and buybacks). As of June 30th, 2015, our net cash position was R$ 4,818 million. Ambev S.A. (NYSE:ABEV) belongs to Consumer Goods sector. Its weekly performance is 2.16%. On last trading day company shares ended up $5.68. Ambev S.A. (NYSE:ABEV) distance from 50-day simple moving average (SMA50) is -4.81%.
On 3 August, Array BioPharma Inc. (NASDAQ:ARRY) reported a profit of $9.4 million for its fiscal year that ended June 30, despite a loss of $12.7 million for the final quarter of the fiscal year. The Boulder-based biopharmaceutical company reported revenue of $51.9 million for the fiscal year, compared with revenue of $42.1 million for fiscal 2014. The $9.4 million profit equated to 6 cents per share compared with a loss of $85.3 million, or 7 cents per share reported in fiscal 2014.On 04 August, Array BioPharma Inc. (NASDAQ:ARRY) shares moved up 2.11% and was closed at $5.81. ARRY EPS growth in last 5 year was 23.70%. Array BioPharma Inc. (NASDAQ:ARRY) year to date (YTD) performance is 22.83%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced that it has entered into an exclusive worldwide licensing agreement with Johns Hopkins University for [18F]DCFPyL (“PyL”), a clinical-stage prostate specific membrane antigen (PSMA)-targeted imaging agent for prostate cancer. PyL, when used in conjunction with high-resolution PET imaging, has shown potential for use in identifying prostate cancer and sites of relapse. Financial terms of the transaction were not disclosed. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ended the last trading day at $8.52. Company weekly volatility is calculated as 9.54% and price to cash ratio as 5.47. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) showed a weekly performance of -9.55%.
On 27 JU;y, Alon Blue Square Israel Ltd (NYSE:BSI) announced that following the previously announced plan of recovery and arrangement of its subsidiary, Mega Retail and the approval of the arrangement by its board of directors, the Company has reached understandings with Israel Discount Bank Ltd. Under the understanding reached, the on-call loan provided by Israel Discount Bank Ltd. to the Company will be extended to September 30, 2015, during which period the Company will not be required to make any principal payments to any of the banks and/or bondholders. Alon Blue Square Israel Ltd (NYSE:BSI) shares advanced 0.46% in last trading session and ended the day at $0.91. BSI Gross Margin is 22.30% and its return on assets is -5.00%. Alon Blue Square Israel Ltd (NYSE:BSI) quarterly performance is -65.01%.